POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
| Autor: | L. D. Shkolnik, E. I. Emelina, Yu. V. Vasyuk, V. V. Nesvetov, E. L. Shkolnik, G. V. Varlan, G. E. Gendlin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Bradycardia
medicine.medical_specialty Anthracycline medicine.medical_treatment 030232 urology & nephrology RM1-950 chemotherapy 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Heart rate anthracycline cardiotoxicity medicine Diseases of the circulatory (Cardiovascular) system Pharmacology (medical) prevention of left ventricle systolic dysfunction Chemotherapy Cardiotoxicity Ejection fraction business.industry ivabradine medicine.disease 030220 oncology & carcinogenesis Anesthesia RC666-701 Cardiology Therapeutics. Pharmacology medicine.symptom Cardiology and Cardiovascular Medicine business Ivabradine medicine.drug |
| Zdroj: | Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 13, Iss 2, Pp 184-190 (2017) |
| ISSN: | 2225-3653 1819-6446 |
| Popis: | Aim. To study the efficacy of ivabradine in the prevention of cardiotoxic effects due to chemotherapeutic drugs in patients with breast cancer. Material and methods. The open randomized uncontrolled study included 55 patients with breast cancer who had to undergo chemotherapy by anthracyclines. The inclusion criterion was a heart rate >70 beats/min. Collection of complaints and anamnesis, ECG, echocardiography, routine laboratory tests were performed in all patients initially and after 1, 3, 6 and 12 months. All patients were treated with polychemotherapy with anthracyclines in combination with cyclophosphamide and fluorouracil. The patients included into the study were randomized into two groups. Patients of the main group (n=23) were additionally prescribed ivabradine in a daily dose of 10 mg followed by a dose titration. Patients of the control group (n=32) received only polychemotherapy. Results. In the main group a decrease in heart rate was observed already by the first month (from 83.6±9.5 to 67.1±7.5 beats/min, p0.05). A significant change in the LV ejection fraction was not found in both groups. Significant differences in LV global longitudinal strain were found between groups in 1, 3 and 6 months of observation (p70 beats/min was safe and did not cause bradycardia. Ivabradine use was accompanied by a significant reduction in a number of patients with complaints of palpitation, contributed to the preservation of normalLV global longitudinal deformation in chemotherapy, while the control group had negative changes with a maximum by the 6th month of follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|